Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
NOTE

Restricted Isotypic Antibody Reactivity to Hepatitis C Virus Synthetic Peptides in Immunocompromised Patients

Marisol Devesa, Arlette de Saez, Graciela León, Firelei Sirit, Clarisa Cosson, Henry Bermúdez, Ferdinando Liprandi, Oscar Noya, Flor H. Pujol
Marisol Devesa
Laboratorio de Biologı́a de Virus, Centro de Microbiologı́a y Biologı́a Celular, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlette de Saez
Banco Municipal de Sangre, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graciela León
Banco Municipal de Sangre, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Firelei Sirit
Planta Procesadora de Derivados Sanguı́neos, Quimbiotec,Instituto Venezolano de Investigaciones Cientı́ficas,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clarisa Cosson
Laboratorio de Biologı́a de Virus, Centro de Microbiologı́a y Biologı́a Celular, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Bermúdez
Laboratorio de Sı́ntesis de Péptidos, Sección de Biohelmintiasis, Instituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferdinando Liprandi
Laboratorio de Biologı́a de Virus, Centro de Microbiologı́a y Biologı́a Celular, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar Noya
Laboratorio de Sı́ntesis de Péptidos, Sección de Biohelmintiasis, Instituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flor H. Pujol
Laboratorio de Biologı́a de Virus, Centro de Microbiologı́a y Biologı́a Celular, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CDLI.6.2.279-281.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

An enzyme immunoassay based on three synthetic peptides from the core, NS4, and NS5 regions of hepatitis C virus allowed the detection of antibodies in 100% of immunocompetent infected patients and in 91% of immunocompromised patients (hemodialysis and hemophiliac patients). Immune impairment seemed to restrict the spectrum of antibody isotypes reacting to the core peptide.

Synthetic peptides have proven to be valuable tools for immunodiagnosis of hepatitis C virus (HCV) infection (8, 10, 18). Most of the available serological tests for HCV are based on the combined use of synthetic peptides and recombinant proteins. In a previous study, restricted antibody reactivity to HCV peptides was observed in HCV-infected hemodialysis patients, although some immunodominant epitopes in the core and NS4 regions were still consistently recognized (5). The aim of this study was to design an immunodiagnostic system for HCV based exclusively on synthetic peptides and suitable for epidemiological studies. In addition, isotypic antibody reactivity to these peptides was evaluated and compared between immunocompromised and immunocompetent HCV-infected patients.

A total of 105 sera from HCV-infected hemodialysis patients previously tested for viral hepatitis serological markers (16) were used in this study. Hemophiliac patient sera (24 hemophilia A patients) were also tested. Both hemophiliac and hemodialysis patients were defined as immunocompromised HCV-infected patients in this study. HCV-positive blood donors and other HCV-infected patients (n = 66) without any evident cause of immunosuppression were also included. Information about the genotypes of HCV circulating in 51 of these patients (17) was available: genotypes 1a, 1b, 2a, 2b, 3a, and 4 (14, 15, 8, 6, 1, and 1 patients, respectively) and six mixed infections were present in the patients analyzed. All patients were human immunodeficiency virus (HIV) negative except for one hemophiliac patient. A total of 96 sera from blood donors, negative for hepatitis B virus (HBV), HCV, and HIV markers, were also tested.

Core peptides (716 [20-mer], RNTYRRPQDVKFPGGGQIVG [amino acids {aa} 13 to 32]; 286 [40-mer], STNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRG [aa 2 to 41]), NS4 peptides (59 [20-mer], AFASRGNHVSPTHYVPESDA [aa 1920 to 1941]), and NS5 peptides (290 [35-mer], RKFPPALPIWARPDYNPPLLESWKDPDYVPPVVHG [aa 2279 to 2313]) were manually synthesized (9, 13) and were based on the consensus sequence of the HCV database (14). The immunodominant antigenic region NS3f (2) was modeled with long peptides (aa 1359 to 1408, 50-mer; aa 1409 to 1448, 40-mer; aa 1449 to 1488, 40-mer), but no significant reactivity was obtained (data not shown). All peptides were synthesized as monomers and polymers, as previously described (15).

Antibody reactivity to the peptides was tested by enzyme immunoassay, as previously described (5). Whether tested singly or as a mixture, 1 μg of each peptide was adsorbed to wells. Human sera were tested at a 1/40 dilution in 1% skim milk in phosphate-buffered saline by using for detection a 10−5 dilution of peroxidase-labelled goat anti-human immunoglobulin G (IgG) (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) in the same buffer. Subclass-specific antibodies to each peptide were tested at the same serum dilution by using anti-isotype-specific monoclonal antibodies conjugated to biotin (Sigma Chemical Co., St. Louis, Mo.), each at a pretested optimal dilution, and streptavidin-peroxidase (1/1,000) (Sigma). TMB (3,3′,5,5′-tetramethylbenzidine) (Bio-Rad Laboratories) was used as a substrate. Cutoff values were determined as means of negative serum values plus 3 standard deviations. Statistical differences were evaluated by the chi square and/or Fisher exact test with Yates’ correction, according to a computerized Epi Info program, version 5.01b (Centers for Disease Control and Prevention, Atlanta, Ga.). Average statistical differences were evaluated by the Studentt test.

The antibody reactivity to a 40-mer peptide (peptide 286) designed from the N-terminal region of the HCV core protein was significantly higher than that directed to a 20-mer peptide (peptide 716) derived from a region located inside the 40-mer peptide and previously found to be the most frequently recognized in this region (5). Of 35 hemodialysis patient sera tested, 31 (89%) recognized peptide 286 while only 24 (69%) reacted with peptide 716, and a significantly higher optical density (OD) was observed for 14 patients with peptide 286 (Table 1). The use of longer peptides in the core region has previously been suggested by others to be more effective (21). In the region shared by the two peptides, an amino acid change was introduced in the 40-mer peptide, 286, since it was more frequently found in the sequences of the different HCV isolates; this may have contributed to the increased reactivity observed with peptide 286. The length and conservation of peptide 286 ensured appropriate reactivity of sera of patients infected with all of the genotypes tested in this study (data not shown).

View this table:
  • View inline
  • View popup
Table 1.

Enhanced reactivity to a 40-mer core peptide by HCV-infected hemodialysis patient sera  (n = 35)

No significant increase in reactivity was detected by using polymeric peptides instead of monomers (data not shown). When a mixture of peptides 286, 59, and 290, derived from the core, NS4, and NS5, respectively, was evaluated as a potential diagnostic antigen for HCV infection, high sensitivity and specificity were obtained with immunocompetent patients (66 of 66 patients recognized [100%] and 1 of 96 reactive among negative patient sera [99% specificity]). The mixture, however, was recognized by only 91% of the immunocompromised HCV-infected patients (118 of 129). The presence of an NS3 antigen in the cocktail used may be critical for adequate recognition of this particular group of patients (3-5). Nevertheless, the peptide cocktail analyzed in this study seems to be useful for epidemiological studies in the general population.

The NS5 region was included, as it has been suggested that the use of NS5 antigens may add sensitivity to diagnostic tests (20). In fact, some HCV-infected hemodialysis patient sera from the group studied by Devesa et al. (5) reacted only with peptide 232 from the NS5 region, which is comprised in peptide 290 used in this study (data not shown). A small portion of the 290 peptide is well conserved among different HCV isolates (aa 2288 to 2297). This might explain the frequent recognition of peptide 290 by the sera of patients tested in this study, irrespective of the infecting genotype (data not shown).

The 20-mer peptide derived from NS4 (peptide 59) and included in the cocktail contains a sequence highly conserved among different HCV isolates, which might be one of the reasons for its high frequency of recognition (5, 10, 11). Antibodies against peptide 59 seem to be raised at early stages of infection, with some degree of antigenic cross-reactivity with proteins from different origins (24). In our study, the use of peptide 59 in the cocktail did not produce nonspecific reactions. The only false-positive result was due to recognition of the core peptide, where some nonspecific reaction has also been described (23).

The antibody subclass reactivity was assayed for each of the three peptides from the core, NS4, and NS5. For the latter two peptides, the isotypic reactivity was mostly of the IgG1 subtype, a reactivity similar to that observed in region NS4a (20, 25). No significant differences were found in the isotypic reactivities between immunocompetent and immunocompromised patients (data not shown). Only in two hemodialysis patient sera was the highest reactivity, to both NS4 and NS5 peptides, of the IgG3 subclass (data not shown).

For the core peptide, IgG1 reactivity was observed in all patients. Antibodies of IgG3, IgG4, and/or IgA were found in 44% of immunocompetent HCV-infected patients but in significantly fewer immunocompromised patients, particularly in HBV-infected patients (Table 2). Reactivity to the core region has previously been shown to be predominantly by IgG1 antibodies, although all other isotypes, particularly IgG3, have been detected (6, 19, 22). A similar pattern was found for the 40-mer peptide 286, although IgG3 and IgG4 were present at similar frequencies (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Isotype reactivity to HCV peptides

The intrinsic immune deficit in hemodialysis patients has already been described (7), and acquired immune impairment has been reported for hemophiliac patients (1, 12). The restricted isotypic response to peptide 286 in both hemodialysis and hemophiliac patients may be due to some degree of impairment of the immune function. Among hemodialysis patients, this effect was more pronounced in HBV-coinfected patients, who were indeed the group with more-reduced reactivity to HCV peptides (5). These results stress the need for highly sensitive diagnostic tools for immunocompromised patients.

ACKNOWLEDGMENTS

This work was supported by grant S1-96000064 from CONICIT, Venezuela, and by Proyecto PCEE.PNUD.VEN/96/002.

FOOTNOTES

    • Received 18 September 1998.
    • Returned for modification 23 November 1998.
    • Accepted 28 December 1998.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Antonace S.,
    2. Jirillo E.,
    3. Stassi D.,
    4. De Mitrio V.,
    5. La Via M. F.,
    6. Bonomo L.
    Immunoresponsiveness in hemophilia: lymphocyte- and phagocyte-mediated functions. Diagn. Clin. Immunol. 5 1988 318 325
    OpenUrlPubMed
  2. 2.↵
    1. Claeys H.,
    2. Volckaerts A.,
    3. Mertens W.,
    4. Liang Z.,
    5. Fiten P.,
    6. Opdenakker G.
    Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus. J. Med. Virol. 45 1995 273 281
    OpenUrlPubMed
  3. 3.↵
    1. Courouce A.-M.,
    2. Le Marrec N.,
    3. Girault A.,
    4. Ducamp S.,
    5. Simon N.
    Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 34 1994 790 795
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Courouce A.-M.,
    2. Barin F.,
    3. Botté C.,
    4. Lunel F.,
    5. Maisonneuve P.,
    6. Maniez M.,
    7. Trépo C.
    A comparative evaluation of the sensitivity of seven anti-hepatitis C virus screening tests. Vox Sang. 69 1995 213 216
    OpenUrlPubMed
  5. 5.↵
    1. Devesa M.,
    2. Khudyakov Y. E.,
    3. Capriles F.,
    4. Blitz L.,
    5. Fields H. A.,
    6. Liprandi F.,
    7. Pujol F. H.
    Reduced antibody reactivity to hepatitis C virus antigens in hemodialysis patients coinfected with hepatitis B virus. Clin. Diagn. Lab. Immunol. 4 1997 639 642
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Gabrielli A.,
    2. Zhang Z.-X.,
    3. Cherubi G.,
    4. Candela M.,
    5. Savoldi S.,
    6. Manzin A.,
    7. Clementi M.,
    8. Amoroso A.,
    9. Sällberg M.
    Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clin. Exp. Immunol. 105 1996 59 64
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Goldblum S. E.,
    2. Reed W. P.
    Host defenses and immunological alterations associated with chronic hemodialysis. Ann. Intern. Med. 93 1980 597 613
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Hosein B.,
    2. Fang C. T.,
    3. Popovsky M. A.,
    4. Ye J.,
    5. Zhang M.,
    6. Wang C. Y.
    Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proc. Natl. Acad. Sci. USA 88 1991 3647 3651
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Houghton R. A.
    Simultaneous multiple peptide synthesis. Proc. Natl. Acad. Sci. USA 82 1985 5131 5135
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Khudyakov Y. E.,
    2. Khudyakova N. S.,
    3. Jue D. L.,
    4. Lambert S. B.,
    5. Fang S.,
    6. Fields H. A.
    Linear B-cell epitopes of the NS3-NS4-NS5 proteins of the hepatitis C virus as modeled with synthetic peptides. Virology 206 1995 666 672
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Logombardo G.,
    2. Ferri C.,
    3. Marchi S.,
    4. Costa F.,
    5. Lombardini F.,
    6. Vacri L.,
    7. Bombardieri S.,
    8. Migliorini P.
    Immune response to an epitope of the NS4 protein of hepatitis C virus in HCV-related disorders. Clin. Immunol. Immunopathol. 87 1998 124 129
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Meijer K.,
    2. Smid W. M.,
    3. Verspiek S. P.,
    4. Smit J. W.,
    5. van der Meer J.
    Differences in immune response between HCV positive, HIV negative haemophilia A and B patients. Thromb. Haemostasis 79 1998 59 61
    OpenUrlPubMed
  13. 13.↵
    1. Merrifield R. B.
    Solid-phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85 1963 2149 2154
    OpenUrlCrossRef
  14. 14.↵
    1. Mizokami M.,
    2. Shin-I T.,
    3. Gojobori T.
    HCV data base, version 1. 1997 National Institute of Genetics Mishima, Japan
  15. 15.↵
    1. Patarroyo M. E.,
    2. Amador R.,
    3. Clavijo P.,
    4. Moreno A.,
    5. Guzmán F.,
    6. Romero P.,
    7. Tascón R.,
    8. Franco A.,
    9. Murillo L.,
    10. Pontón G.,
    11. Trujillo G.
    A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 1988 158 161
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Pujol F. H.,
    2. Ponce J. G.,
    3. Lema M. G.,
    4. Capriles F.,
    5. Devesa M.,
    6. Sirit F.,
    7. Salazar M.,
    8. Vásquez G.,
    9. Monsalve F.,
    10. Blitz-Dorfman L.
    High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J. Clin. Microbiol. 34 1996 1633 1636
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Pujol F. H.,
    2. Loureiro C. L.,
    3. Devesa M.,
    4. Blitz L.,
    5. Parra K.,
    6. Beker S.,
    7. Liprandi F.
    Determination of genotypes of hepatitis C virus from Venezuelan isolates by restriction fragment length polymorphism. J. Clin. Microbiol. 35 1997 1870 1872
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Roggendorf M.,
    2. Lu M.,
    3. Meisel H.,
    4. Riffelmann M.,
    5. Schreier E.,
    6. Viazov S.
    Rational use of diagnostic tools in hepatitis C. J. Hepatol. 24 (Suppl. 2) 1996 26 34
    OpenUrlPubMedWeb of Science
  19. 19.↵
    1. Sällberg M.,
    2. Rudén U.,
    3. Wahren B.,
    4. Magnius L. O.
    Immune response to a single peptide containing an immunodominant region of hepatitis C virus core protein: the isotypes and the recognition site. Immunol. Lett. 33 1992 27 34
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Sällberg M.,
    2. Rudén U.,
    3. Wahren B.,
    4. Magnius L. O.
    Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site within the envelope 1 protein. Clin. Exp. Immunol. 91 1993 489 494
    OpenUrlPubMed
  21. 21.↵
    1. Sato A.,
    2. Sho Y.,
    3. Nakamura H.,
    4. Kunitomo T.,
    5. Arima T.
    Immune response of blood donors to peptides of various lengths and those with genotypic sequence variations corresponding to the N-terminal portion of the core protein of hepatitis C virus. J. Med. Virol. 44 1994 88 91
    OpenUrlPubMed
  22. 22.↵
    1. Siemoneit K.,
    2. da Silva Cardoso M.,
    3. Wolpl A.,
    4. Epple S.,
    5. Wintersinger H.,
    6. Koerner K.,
    7. Kubanek B.
    Isotype-specific immune response to a single hepatitis C virus core epitope defined by a human monoclonal antibody: diagnostic value and correlation to PCR. Ann. Hematol. 69 1994 129 133
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Tobler L. H.,
    2. Busch M.,
    3. Peterson J.,
    4. Kochesky R.,
    5. Bahl C.,
    6. Lee S. R.
    Identification of a crossreactive epitope within hepatitis C virus core antigen: resolution by third-generation hepatitis C virus assays. Transfusion 36 1996 581 582
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Wienhues U.,
    2. Ihlenfeldt H.-G.,
    3. Seidel C.,
    4. Schmitt U.,
    5. Kraas W.,
    6. Jung G.
    Characterization of a linear epitope in the nonstructural region 4 of hepatitis C virus with reactivity to seroconversion antibodies. Virology 245 1998 281 288
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Zhang Z.-X.,
    2. Chen M.,
    3. Hultgren C.,
    4. Birkett A.,
    5. Milich D. R.,
    6. Sällberg M.
    Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. J. Gen. Virol. 78 1997 2735 2746
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Restricted Isotypic Antibody Reactivity to Hepatitis C Virus Synthetic Peptides in Immunocompromised Patients
Marisol Devesa, Arlette de Saez, Graciela León, Firelei Sirit, Clarisa Cosson, Henry Bermúdez, Ferdinando Liprandi, Oscar Noya, Flor H. Pujol
Clinical and Diagnostic Laboratory Immunology Mar 1999, 6 (2) 279-281; DOI: 10.1128/CDLI.6.2.279-281.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Restricted Isotypic Antibody Reactivity to Hepatitis C Virus Synthetic Peptides in Immunocompromised Patients
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Restricted Isotypic Antibody Reactivity to Hepatitis C Virus Synthetic Peptides in Immunocompromised Patients
Marisol Devesa, Arlette de Saez, Graciela León, Firelei Sirit, Clarisa Cosson, Henry Bermúdez, Ferdinando Liprandi, Oscar Noya, Flor H. Pujol
Clinical and Diagnostic Laboratory Immunology Mar 1999, 6 (2) 279-281; DOI: 10.1128/CDLI.6.2.279-281.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X